You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物-B(01877.HK)預計一季度營業收入同比增長89.69%-152.92%
格隆匯 03-19 22:32

格隆匯3月19日丨君實生物-B(01877.HK)公佈,截至2020年3月31日止3個月,預計公司實現營業收入1.5億-2億元,同比增長89.69%-152.92%;歸屬於公司普通股股東的淨虧損1.98億-2.33億元,同比擴大37.10%-46.45%。

2020年一季度公司收入預計同比去年同期增幅較大,主要原因為:公司產品"特瑞普利單抗"於2018年12月正式獲得國家藥品監督管理局有條件批准上市並於2019年2月末起開展銷售,憑藉市場先發優勢、良好的產品臨牀療效、產品價格優勢、經驗豐富的銷售團隊、高效的銷售組織體系建設和符合產品特性的市場推廣方案,預計公司2020年一季度收入較2019年一季度增幅較大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account